Crowdonomics
U.S. Stem Cell, Inc.

Reg A+ · Equity · Aug 2021

ClosedReg A+Equity
via the platform · last checked Aug 16, 2026
Raised
$0 / $2.5M max
0% of ceiling
Investors
—
—
Estimated pre-money
$4.5M
—

Financials disclosed in this offering

FY2020 · hover for source
$277K
−$2.9M
FY2020
RevenueNet income
Metric
FY2020 audited
Income statement
Revenue
$277,087
Cost of goods sold
$64,117
Gross margin
77%
Net income
-$2,890,493
Taxes paid
$0
Balance sheet
Cash
$18,570
Accounts receivable
$54,164
Total assets
$88,152
Short-term debt
$1,397,762
Long-term debt
$7,684,892
Total liabilities
$11,667,444
Other
Headcount
3

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Est. pre-money$4.5M
Price / share$0.01
Shares offered250,000,000

Estimated, not stated: $0.01 × 451,738,971 securities outstanding.

Offering details

Target—
Max$2,500,000
Min investment—
OpenedAug 30, 2021
Deadline—
Days active1,866

Links & provenance

Source: SEC EDGAR
0001185185-21-001210
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.